BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17094432)

  • 1. Vessel dilator and kaliuretic peptide inhibit ERK 1/2 activation in human prostate cancer cells.
    Sun Y; Eichelbaum EJ; Wang H; Vesely DL
    Anticancer Res; 2006; 26(5A):3217-22. PubMed ID: 17094432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells.
    Sun Y; Eichelbaum EJ; Skelton WP; Lenz A; Wang H; Vesely DL
    Anticancer Res; 2009 Apr; 29(4):971-5. PubMed ID: 19414334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells.
    Sun Y; Eichelbaum EJ; Wang H; Vesely DL
    Anticancer Res; 2007; 27(3B):1387-92. PubMed ID: 17595752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells.
    Sun Y; Eichelbaum EJ; Wang H; Vesely DL
    Anticancer Res; 2006; 26(6B):4143-8. PubMed ID: 17201125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial natriuretic peptide and long-acting natriuretic peptide inhibit ras in human prostate cancer cells.
    Sun Y; Eichelbaum EJ; Lenz A; Skelton WP; Wang H; Vesely DL
    Anticancer Res; 2009 Jun; 29(6):1889-93. PubMed ID: 19528444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac hormones activate ERK 1/2 kinases in human fibroblasts.
    Sun Y; Eichelbaum EJ; Wang H; Vesely DL
    Horm Metab Res; 2009 Mar; 41(3):197-201. PubMed ID: 18855305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four peptide hormones decrease the number of human breast adenocarcinoma cells.
    Vesely BA; Song S; Sanchez-Ramos J; Fitz SR; Solivan SM; Gower WR; Vesely DL
    Eur J Clin Invest; 2005 Jan; 35(1):60-9. PubMed ID: 15638821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four peptide hormones' specific decrease (up to 97%) of human prostate carcinoma cells.
    Vesely BA; Alli AA; Song SJ; Gower WR; Sanchez-Ramos J; Vesely DL
    Eur J Clin Invest; 2005 Nov; 35(11):700-10. PubMed ID: 16269020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells.
    Sun Y; Eichelbaum EJ; Wang H; Vesely DL
    Anticancer Res; 2007; 27(6B):3813-8. PubMed ID: 18225537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five cardiac hormones decrease the number of human small-cell lung cancer cells.
    Vesely BA; Song S; Sanchez-Ramos J; Fitz SR; Alli AA; Solivan SM; Gower WR; Vesely DL
    Eur J Clin Invest; 2005 Jun; 35(6):388-98. PubMed ID: 15948900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vessel dilator: most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of human squamous lung cancer cells.
    Vesely BA; Fitz SR; Gower WR; Vesely DL
    Cancer Lett; 2006 Feb; 233(2):226-31. PubMed ID: 15893414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.
    Vesely DL; Perez-Lamboy GI; Schocken DD
    Metabolism; 2000 Dec; 49(12):1592-7. PubMed ID: 11145122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic approach for cancer using four cardiovascular hormones.
    Vesely DL; Clark LC; Garces AH; McAfee QW; Soto J; Gower WR
    Eur J Clin Invest; 2004 Oct; 34(10):674-82. PubMed ID: 15473892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.
    Chiou S; Vesely DL
    Endocrinology; 1995 May; 136(5):2033-9. PubMed ID: 7720651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease circulating prolactin concentrations.
    Vesely DL; San Miguel GI; Hassan I; Schocken DD
    Horm Metab Res; 2002 May; 34(5):245-9. PubMed ID: 12063637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via cyclic GMP.
    Gower WR; Vesely BA; Alli AA; Vesely DL
    Int J Gastrointest Cancer; 2005; 36(2):77-87. PubMed ID: 16648657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of AKT in human pancreatic, renal and colorectal cancer cells by four cardiac hormones.
    Skelton WP; Skelton M; Vesely DL
    Anticancer Res; 2013 Mar; 33(3):785-90. PubMed ID: 23482745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four cardiac hormones cause death of human cancer cells but not of healthy cells.
    Skelton WP; Pi GE; Vesely DL
    Anticancer Res; 2011 Feb; 31(2):395-402. PubMed ID: 21378317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones.
    Vesely DL; Eichelbaum EJ; Sun Y; Alli AA; Vesely BA; Luther SL; Gower WR
    In Vivo; 2007; 21(3):445-51. PubMed ID: 17591353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor's activation of Ras is inhibited by four cardiac hormones.
    Sun Y; Eichelbaum EJ; Lenz A; Wang H; Vesely DL
    Eur J Clin Invest; 2010 May; 40(5):408-13. PubMed ID: 20353436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.